SPI-1005 for the Treatment of Meniere's Disease (Open Label)

Abroad (travel likely)RecruitingPHASE3

Conditions

Meniere's Disease · Ménière's Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The House Institute, Los Angeles, California, United States
Study coordinator · clinicaltrials@hifla.org · (213) 443-8193
ENT and Allergy Associates of Florida, Boynton Beach, Florida, United States
Contact: Study coordinator (Clinical Research Supervisor) · pamanley@entaaf.com · 954-575-9301
ENT and Allergy Associates of Florida, Delray Beach, Florida, United States
Contact: Study coordinator (Clinical Research Supervisor) · pamanley@entaaf.com · (561) 939 - 0186
Northwell Health, New Hyde Park, New York, United States
Contact: Study coordinator (Clinical Research Manager) · gmullool@northwell.edu · 718-470-7974
ENT and Allergy Associates, LLP, New York, New York, United States
Contact: Study coordinator (Ginny Mullooly) · gmullool@northwell.edu · 718-470-7974
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Maya Childs) · Maya.Childs@jefferson.edu · (215) 955-6760
Medical University of South Carolina, Charleston, South Carolina, United States
Contact: Study coordinator (Research Director) · nguyensh@musc.edu · (843)792-1356
University of Texas Southwestern, Dallas, Texas, United States
Contact: Study coordinator (Paula Arellano-Cruz) · paula.arellano-cruz@utsouthwestern.edu · 214-648-8096
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact: Study coordinator (Clinical Research Coordinator) · smleziva@mcw.edu · 414.955.0822

View source on ClinicalTrials.gov